STANDARD BIOTOOLS INC. (LAB)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenue | 21,762 | 40,795 | 44,969 | |
| Product | 7,608 | - | - | |
| Services And Other Revenue | 3,526 | - | - | |
| Total cost of revenue | 11,134 | 21,054 | 21,708 | |
| Gross profit | 10,628 | 19,741 | 23,261 | |
| Selling, general and administrative | 28,105 | 38,707 | 34,403 | |
| Restructuring and related charges | 1,727 | 1,552 | 2,341 | |
| Research and development | 6,222 | 11,328 | 13,156 | |
| Transaction and integration expenses | 271 | 1,124 | 5,079 | |
| Total operating expenses | 36,325 | 52,711 | 54,979 | |
| Loss from continuing operations | -25,697 | -32,970 | -31,718 | |
| Interest income | 2,461 | 2,916 | 3,941 | |
| Interest expense | 9 | 2 | - | |
| Bargain purchase gain | - | - | - | |
| Other income (expense), net | 4,963 | 3,872 | 957 | |
| Loss from continuing operations before income taxes | -18,282 | -26,184 | -26,820 | |
| Income tax benefit (expense) | -609 | -151 | 118 | |
| Net loss from continuing operations | -17,673 | - | - | |
| Loss from discontinued operations, net of tax | -15,786 | - | - | |
| Net loss | -33,459 | -26,033 | -26,938 | |
| Induced conversion of redeemable preferred stock | - | - | - | |
| Net loss attributable to common stockholders | -33,459 | -26,033 | -26,938 | |
| Earnings per share, basic | -0.09 | -0.07 | -0.07 | |
| Earnings per share, diluted | -0.09 | -0.07 | -0.07 | |
| Weighted average number of shares outstanding, basic, total | 380,498,000 | 378,228,000 | 371,538,000 | |
| Weighted average number of shares outstanding, diluted, total | 380,498,000 | 378,228,000 | 371,538,000 | |